Emergent BioSolutions Inc. (NYSE:EBS) Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund grew its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 41.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 306,286 shares of the biopharmaceutical company's stock after acquiring an additional 90,113 shares during the period. New York State Common Retirement Fund owned about 0.57% of Emergent BioSolutions worth $2,928,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. State Street Corp raised its holdings in shares of Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company's stock valued at $15,960,000 after purchasing an additional 1,713,200 shares in the last quarter. Oak Hill Advisors LP purchased a new stake in shares of Emergent BioSolutions in the third quarter valued at about $9,296,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Emergent BioSolutions during the fourth quarter worth about $1,831,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Emergent BioSolutions during the third quarter worth about $1,547,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in Emergent BioSolutions in the 3rd quarter valued at about $295,000. Hedge funds and other institutional investors own 78.40% of the company's stock.

Emergent BioSolutions Stock Performance

EBS traded down $0.60 during trading on Wednesday, reaching $5.80. The company's stock had a trading volume of 1,791,073 shares, compared to its average volume of 2,669,735. The company has a market capitalization of $314.00 million, a price-to-earnings ratio of -1.41 and a beta of 1.62. The company's fifty day moving average price is $9.43 and its 200-day moving average price is $9.02. Emergent BioSolutions Inc. has a 52-week low of $1.82 and a 52-week high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Remove Ads

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.40. The firm had revenue of $194.70 million for the quarter, compared to the consensus estimate of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same period in the previous year, the business earned ($0.77) earnings per share. On average, equities analysts forecast that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. StockNews.com downgraded Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday. Benchmark increased their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.